ImmuneMed, Inc.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) (NCT06306339) | ImmuneMed, Inc. | 2024-03-01 |
| A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) (NCT05808335) | ImmuneMed, Inc. | 2022-01-11 |
| Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia (NCT04679350) | ImmuneMed, Inc. | 2021-03-18 |
| Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia (NCT04679415) | ImmuneMed, Inc. | 2020-12-17 |
| Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia (NCT04676971) | ImmuneMed, Inc. | 2020-12-11 |
| Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration) (NCT04817202) | ImmuneMed, Inc. | 2020-09-16 |
| Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers (NCT03653208) | ImmuneMed, Inc. | 2018-11-20 |
Track ImmuneMed, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.